Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain.

Autor: P, Huang X, E, Williams F, M, Peseckis S, S, Messer W

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; September 1998, Vol. 286 Issue: 3 p1129-39, 11p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

ChemInform Abstract: Chemistry and Positive Inotropic Effect of Pelrinone and Related Derivatives. A Novel Class of 2-Methylpyrimidones as Inotropic Agents.

Autor: BAGLI, J., BOGRI, T., PALAMETA, B., RAKHIT, S., PESECKIS, S., MCQUILLAN, J., LEE, D. K. H.

Publikováno v: ChemInform; Aug1988, Vol. 19 Issue 33, pno-no, 1p

Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.

Autor: Messer WS Jr; Department of Medicinal and Biological Chemistry, College of Pharmacy, University of Toledo, OH 43606, USA., Rajeswaran WG, Cao Y, Zhang HJ, el-Assadi AA, Dockery C, Liske J, O'Brien J, Williams FE, Huang XP, Wroblewski ME, Nagy PI, Peseckis SM

Publikováno v: Pharmaceutica acta Helvetiae [Pharm Acta Helv] 2000 Mar; Vol. 74 (2-3), pp. 135-40.

Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors.

Autor: Huang XP; Department of Pharmacological Sciences, Diabetes and Metabolic Diseases Research Center, School of Medicine, Health Science Center, State University of New York at Stony Brook, Stony Brook, New York, USA., Williams FE, Peseckis SM, Messer WS Jr

Publikováno v: Molecular pharmacology [Mol Pharmacol] 1999 Oct; Vol. 56 (4), pp. 775-83.